Company to present updated preliminary results from ENLIGHTED Phase 3 Study in LG UTUC  Additional podium presentation to provide updates from long-term evaluation of Padelipor  n VTP in intermediate-risk prostate cancer TEL AVIV, Israel, April 11, 2025 (GLOBE NEWSWIRE) — ImPact Biotech, a clinical-stage biotechnology company focused on developing Padelipor n vascular targeted photodynamic (VTP) … Continued

Complete response (CR) observed in 85% (17/20) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase Padeliporfin VTP treatment continues to be safe and efficacious, establishing profile consistent with prior results alongside additional follow-up in Maintenance Treatment Phase TEL AVIV, Israel, Dec. 04, 2024 (GLOBE NEWSWIRE) — ImPact … Continued

Complete response (CR) observed in 86% (12/14) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase Padeliporfin VTP treatment continues to be safe and efficacious, establishing profile consistent with prior results alongside additional follow-up in Maintenance Treatment Phase TEL AVIV, Israel, Nov. 07, 2024 (GLOBE NEWSWIRE) — ImPact … Continued

TEL AVIV, Israel, Oct. 25, 2024 (GLOBE NEWSWIRE) — ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporn vascular targeted photodynamic (VTP) therapy to treat a range of solid tumors, today announced an abstract including interim results from ENLIGHTED, the Company’s ongoing Phase 3 study of Padeliporn VTP treatment of patients with low-grade upper … Continued

TEL AVIV, Israel, Sept. 25, 2024 (GLOBE NEWSWIRE) — ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporfin vascular targeted photodynamic (VTP) therapy to treat a range of solid tumors, today announced that management will present a corporate overview at the Oppenheimer Private Life Sciences Company Showcase on October 1 st, 2024 in New … Continued